Lara Malerba

1.2k total citations
18 papers, 261 citations indexed

About

Lara Malerba is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Lara Malerba has authored 18 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Lara Malerba's work include Acute Lymphoblastic Leukemia research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (4 papers). Lara Malerba is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (4 papers). Lara Malerba collaborates with scholars based in Italy, Spain and Austria. Lara Malerba's co-authors include Massimo Offidani, Laura Corvatta, Anna Mele, Giuseppe Visani, Pietro Leoni, Massimo Catarini, Alessandro Isidori, Francesco Gaudio, Barbara Sarina and Giorgina Specchia and has published in prestigious journals such as Blood, Cancer and Supportive Care in Cancer.

In The Last Decade

Lara Malerba

18 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lara Malerba Italy 11 151 131 84 63 52 18 261
Tsuneaki Hirakawa Japan 6 83 0.5× 98 0.7× 71 0.8× 52 0.8× 30 0.6× 20 248
Atsuko Mugitani Japan 8 78 0.5× 94 0.7× 54 0.6× 39 0.6× 37 0.7× 28 219
P. Casassus France 8 129 0.9× 202 1.5× 97 1.2× 104 1.7× 69 1.3× 15 344
Bernard De Prijck Belgium 9 68 0.5× 96 0.7× 96 1.1× 32 0.5× 105 2.0× 24 230
Diane S. Sempek United States 6 143 0.9× 323 2.5× 77 0.9× 39 0.6× 66 1.3× 7 397
Sharon Bergeron United States 8 71 0.5× 57 0.4× 98 1.2× 60 1.0× 38 0.7× 10 291
T Iseki Japan 11 78 0.5× 195 1.5× 62 0.7× 25 0.4× 58 1.1× 20 320
Eric S. Schafer United States 11 92 0.6× 95 0.7× 48 0.6× 115 1.8× 33 0.6× 36 391
José L. Ochoa-Bayona United States 9 168 1.1× 210 1.6× 74 0.9× 110 1.7× 61 1.2× 40 371
Elena Maino Italy 8 66 0.4× 102 0.8× 92 1.1× 23 0.4× 67 1.3× 15 230

Countries citing papers authored by Lara Malerba

Since Specialization
Citations

This map shows the geographic impact of Lara Malerba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lara Malerba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lara Malerba more than expected).

Fields of papers citing papers by Lara Malerba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lara Malerba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lara Malerba. The network helps show where Lara Malerba may publish in the future.

Co-authorship network of co-authors of Lara Malerba

This figure shows the co-authorship network connecting the top 25 collaborators of Lara Malerba. A scholar is included among the top collaborators of Lara Malerba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lara Malerba. Lara Malerba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Martino, Massimo, Barbara Gamberi, Elisabetta Antonioli, et al.. (2024). Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?. Expert Review of Hematology. 17(7). 375–390. 3 indexed citations
2.
Rossi, David, Donatella Sarti, Lara Malerba, et al.. (2016). Secondary Bone Marrow Malignancies after Adjuvant Chemotherapy for Breast Cancer: A Report of 2 Cases and a Review of the Literature. Tumori Journal. 102(2_suppl). S29–S31. 1 indexed citations
3.
Isidori, Alessandro, Cristina Clissa, Federica Loscocco, et al.. (2015). Advancement in high dose therapy and autologous stem cell rescue in lymphoma.. PubMed. 7(7). 1039–46. 6 indexed citations
4.
Offidani, Massimo, Laura Corvatta, Claudia Polloni, et al.. (2011). Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma. Annals of Hematology. 90(12). 1449–1456. 14 indexed citations
5.
Visani, Giuseppe, Lara Malerba, Saveria Capria, et al.. (2011). BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 118(12). 3419–3425. 84 indexed citations
6.
7.
Malerba, Lara, et al.. (2006). Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. European Journal Of Haematology. 76(5). 436–439. 10 indexed citations
8.
Offidani, Massimo, et al.. (2006). Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies. Supportive Care in Cancer. 14(8). 874–877. 4 indexed citations
9.
Visani, Giuseppe, Anna Mele, F D'Adamo, et al.. (2006). An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leukemia & lymphoma. 47(12). 2542–2546. 4 indexed citations
10.
Mele, Anna, Giuseppina Nicolini, F D'Adamo, et al.. (2005). Mini‐ICE effectively mobilises peripheral blood stem cells after fludarabine‐based regimens in acute myeloid leukaemia. European Journal Of Haematology. 74(4). 277–281. 3 indexed citations
11.
Offidani, Massimo, Laura Corvatta, Lara Malerba, Marco Marconi, & Pietro Leoni. (2004). Infectious Complications in Adult Acute Lymphoblastic Leukemia (ALL): Experience at One Single Center. Leukemia & lymphoma. 45(8). 1617–1621. 11 indexed citations
12.
Offidani, Massimo, Laura Corvatta, Attilio Olivieri, et al.. (2004). Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. The Hematology Journal. 5(4). 312–317. 21 indexed citations
13.
Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). Leukemia & lymphoma. 46(2). 233–238. 13 indexed citations
14.
Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates. Cancer. 101(3). 567–577. 10 indexed citations
15.
Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Common and rare side‐effects of low‐dose thalidomide in multiple myeloma: focus on the dose‐minimizing peripheral neuropathy. European Journal Of Haematology. 72(6). 403–409. 34 indexed citations
16.
Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).. Blood. 104(11). 4490–4490. 4 indexed citations
17.
Offidani, Massimo, Laura Corvatta, Riccardo Centurioni, et al.. (2003). High-dose daunorubicin as liposomal compound (Daunoxome®) in elderly patients with acute lymphoblastic leukemia1. The Hematology Journal. 4(1). 47–53. 18 indexed citations
18.
Offidani, Massimo, Anna Mele, Laura Corvatta, et al.. (2002). Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple Myeloma. Leukemia & lymphoma. 43(6). 1273–1280. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tsuneaki Hirakawa Breakdown of academic impact, for papers by Atsuko Mugitani Breakdown of academic impact, for papers by P. Casassus Breakdown of academic impact, for papers by Bernard De Prijck Breakdown of academic impact, for papers by Diane S. Sempek Breakdown of academic impact, for papers by Sharon Bergeron Breakdown of academic impact, for papers by T Iseki Breakdown of academic impact, for papers by Eric S. Schafer Breakdown of academic impact, for papers by José L. Ochoa-Bayona Breakdown of academic impact, for papers by Elena Maino
Rankless by CCL
2026